1 not yet recruiting, 1 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow ASK120067: new trials by email Literature Review of ASK120067 trials Research Report on ASK120067
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. Limertinib+bevacizumab, Limertinib - EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 136 | 2025-06-30 | 2025-05-21 |
| Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer ASK120067 - Locally Advanced or Metastatic NSCLC | Phase 1 / Phase 2 | Unknown | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 507 | 2017-11-30 | 2020-09-16 |
Carcinoma, Non-Small-Cell Lung (1)
Jiangsu Aosaikang Pharmaceutical Co., Ltd. (1) · Shanghai Chest Hospital (1)
China (1)